ANDA 85133, held by Sandoz. Imipramine Hydrochloride.
As of Nov 21, 2026, ANDA 85133 (Imipramine Hydrochloride), held by Sandoz, was first approved by FDA on Mar 13, 1981, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 1981 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Imipramine Hydrochloride50MG · tablet;oral | Imipramine Hydrochloride | Discontinued |
| Apr 20, 1995 | Supplement 19Labeling | Approved | None posted |
| Jul 31, 1992 | Supplement 17Labeling | Approved | None posted |
| Apr 26, 1989 | Supplement 14Labeling | Approved | None posted |
| Sep 11, 1986 | Supplement 9Manufacturing | Approved | None posted |
| Mar 13, 1981 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters